

Gael Nicolas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3195782/gael-nicolas-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

5,255
citations

25
h-index

51
g-index

51
ext. papers

5,743
ext. citations

5.8
avg, IF

4.68
L-index

#	Paper	IF	Citations
47	Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders. <i>Blood</i> , 2021 , 137, 3660-3669	2.2	7
46	Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. <i>Haematologica</i> , 2021 , 106, 913-917	6.6	7
45	A mutation in the iron-responsive element of is a modifier of disease severity in a patient suffering from associated erythropoietic protoporphyria. <i>Haematologica</i> , 2021 , 106, 2030-2033	6.6	2
44	The ubiquitous mitochondrial protein unfoldase CLPX regulates erythroid heme synthesis by control of iron utilization and heme synthesis enzyme activation and turnover. <i>Journal of Biological Chemistry</i> , 2021 , 297, 100972	5.4	4
43	β-spectrin controls calcium-regulated exocytosis in neuroendocrine chromaffin cells through neuronal Wiskott-Aldrich Syndrome protein interaction. <i>IUBMB Life</i> , 2020 , 72, 544-552	4.7	1
42	Iron deficiency markers in patients undergoing iron replacement therapy: a 9-year retrospective real-world evidence study using healthcare databases. <i>Scientific Reports</i> , 2020 , 10, 14983	4.9	4
41	Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation. <i>Blood</i> , 2020 , 135, 441-448	2.2	9
40	Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyrin. <i>American Journal of Human Genetics</i> , 2019 , 104, 341-347	11	17
39	Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. <i>Molecular Genetics and Metabolism</i> , 2019 , 128, 190-197	3.7	13
38	Iron deficiency and anemia in adolescent girls consuming predominantly plant-based diets in rural Ethiopia. <i>Scientific Reports</i> , 2019 , 9, 17244	4.9	5
37	Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation. <i>Cell Death Discovery</i> , 2019 , 5, 150	6.9	25
36	From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2018 , 27, 1164-1173	5.6	42
35	Mutation in human elevates levels of aminolevulinic acid synthase and protoporphyrin IX to promote erythropoietic protoporphyria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E8045-E8052	11.5	50
34	The microbiota shifts the iron sensing of intestinal cells. <i>FASEB Journal</i> , 2016 , 30, 252-61	0.9	52
33	Porphyrias: A 2015 update. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, 412-25	2.4	96
32	LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 1557-67	5.9	39
31	Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis. <i>Blood</i> , 2014 , 124, 441-4	2.2	20

30	Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity. <i>Human Mutation</i> , 2012 , 33, 1388-96	4.7	21
29	Proximal giant neurofilamentous axonopathy in mice genetically engineered to resist calpain and caspase cleavage of β I spectrin. <i>Journal of Molecular Neuroscience</i> , 2012 , 47, 631-8	3.3	2
28	Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?. <i>British Journal of Haematology</i> , 2011 , 152, 498-500	4.5	9
27	Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6. <i>Blood</i> , 2011 , 117, 647-50	2.2	28
26	Hepcidin targets ferroportin for degradation in hepatocytes. <i>Haematologica</i> , 2010 , 95, 501-4	6.6	125
25	A mutant α II-spectrin designed to resist calpain and caspase cleavage questions the functional importance of this process in vivo. <i>Journal of Biological Chemistry</i> , 2007 , 282, 14226-37	5.4	20
24	Spectrin interacts with EVL (Enabled/vasodilator-stimulated phosphoprotein-like protein), a protein involved in actin polymerization. <i>Biology of the Cell</i> , 2006 , 98, 279-93	3.5	30
23	Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. <i>Blood</i> , 2006 , 107, 2952-8	2.2	64
22	Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. <i>Blood</i> , 2005 , 105, 4861-4	4.2	94
21	α II-spectrin interacts with Tes and EVL, two actin-binding proteins located at cell contacts. <i>Biochemical Journal</i> , 2005 , 388, 631-8	3.8	41
20	Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. <i>Hepatology</i> , 2005 , 41, 1056-64	11.2	53
19	Transferrin receptor 1 mRNA is downregulated in placenta of hepcidin transgenic embryos. <i>FEBS Letters</i> , 2004 , 574, 187-91	3.8	29
18	Functional differences between hepcidin 1 and 2 in transgenic mice. <i>Blood</i> , 2004 , 103, 2816-21	2.2	94
17	Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. <i>Blood</i> , 2004 , 103, 2841-3	2.2	41
16	α II-spectrin is an in vitro target for caspase-2, and its cleavage is regulated by calmodulin binding. <i>Biochemical Journal</i> , 2004 , 378, 161-8	3.8	53
15	Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. <i>Nature Genetics</i> , 2003 , 34, 97-101	36.3	255
14	Identification of new partners of the epithelial sodium channel α subunit. <i>Comptes Rendus - Biologies</i> , 2003 , 326, 615-24	1.4	11
13	The AMP-activated protein kinase α 2 catalytic subunit controls whole-body insulin sensitivity. <i>Journal of Clinical Investigation</i> , 2003 , 111, 91-8	15.9	396

12 Hépcidine, un contrôle essentiel de l'absorption du fer. *Medecine/Sciences*, **2002**, 18, 270-271

11 Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4596-601 11.5 678

10 Tyrosine phosphorylation regulates alpha II spectrin cleavage by calpain. *Molecular and Cellular Biology*, **2002**, 22, 3527-36 4.8 87

9 Hepcidin, a new iron regulatory peptide. *Blood Cells, Molecules, and Diseases*, **2002**, 29, 327-35 2.1 229

8 The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *Journal of Clinical Investigation*, **2002**, 110, 1037-1044 15.9 967

7 The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *Journal of Clinical Investigation*, **2002**, 110, 1037-44 15.9 477

6 Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 8780-5 11.5 982

5 Identification of ubiquitinated repeats in human erythroid alpha-spectrin. *FEBS Journal*, **2000**, 267, 2812-9 7

4 Properties of normal and mutant polypeptide fragments from the dimer self-association sites of human red cell spectrin. *European Biophysics Journal*, **1999**, 28, 208-15 1.9 17

3 Spectrin self-association site: characterization and study of beta-spectrin mutations associated with hereditary elliptocytosis. *Biochemical Journal*, **1998**, 332 (Pt 1), 81-9 3.8 43

2 Method of site-directed mutagenesis using long primer-unique site elimination and exonuclease III. *BioTechniques*, **1997**, 22, 430-4 2.5 6

1 CLPX regulates erythroid heme synthesis by control of mitochondrial heme synthesis enzymes and iron utilization 1